Sec Form 4 Filing - Rawcliffe Adrian @ Adaptimmune Therapeutics PLC - 2019-01-04

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Rawcliffe Adrian 2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ ADAP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) 440 SOUTH BROAD STREET, UNIT 2203 3. Date of Earliest Transaction (MM/DD/YY) 01/04/2019 (Street) PHILADELPHIA, PA19146 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option to purchase Ordinary Shares $ 0.89 ( 1 ) 01/04/2019 A 1,257,744 ( 2 ) 01/04/2029 Ordinary Shares 1,257,744 $ 0 1,257,744 D Option to purchase Ordinary Shares $ 0.0013 ( 3 ) 01/04/2019 A 280 ,896 ( 4 ) ( 5 ) Ordinary Shares 280,896 $ 0 280,896 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Rawcliffe Adrian 440 SOUTH BROAD STREET, UNIT 2203 PHILADELPHIA, PA19146 Chief Financial Officer Signatures /s/ Adrian George Rawcliffe 01/08/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. ( 2 )Exercisable as to 314,436 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 26,238 Ordinary Shares on January 4, 2023. ( 3 )The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. ( 4 )Exercisable as to 70,224 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. ( 5 )The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.